益艾康联合逆转录病毒疗法治疗SIV感染猕猴艾滋病模型实验研究  

Experimental Study onTreatment of SIV Infected Rhesus Monkeys AIDSModelbyYiaikang(益艾康)CombinedwithART

作　　者：赵明亮 王琼[1] 刘本波 丁雪[4] 孟鹏飞 徐立然[4] 庞伟[1] 田仁荣[1] 郑永唐[1] ZHAO Mingliang;WANG Qiong;LIU Benbo;DING Xue;MENG Pengfei;XU Liran;PANG Wei;TIAN Renrong;ZHENG Yongtang(Key Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences,Institute of Zoology,Chinese Academy of Sciences,Kunming 650223,Yunnan,China;Faculty of Basic Medicine,Kunming University of Science and Technology,Kunming 650500,Yunnan,China;School of Pharmacy,Dali University,Dali 671000,Yunnan,China;The First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450000,Henan,China)

机构地区：[1]中国科学院昆明动物研究所,云南昆明650223 [2]昆明理工大学医学院,云南昆明650500 [3]大理大学药学院,云南大理671000 [4]河南中医药大学第一附属医院,河南郑州450000

出　　处：《辽宁中医杂志》2023年第3期193-199,共7页Liaoning Journal of Traditional Chinese Medicine

基　　金：国家重点研发计划项目(2021YFC2301703);国家自然科学基金-河南联合基金(U1604287)。

摘　　要：目的 采用猴免疫缺陷病毒(SIVmac239)感染猕猴艾滋病模型,评价中药益艾康联合抗逆转录病毒治疗(ART)的治疗效果。方法 8只SIVmac239病毒感染的猕猴随机分为两组:ART治疗组、益艾康联合ART治疗组。ART治疗先后分别使用洛匹那韦/利托那韦(LPV/r)和恩曲他滨(FTC)+泰诺福韦(PMPA)+雷特格韦(RAL)进行治疗,检测不同治疗时期猕猴体质量、血常规、血生化、血浆病毒载量以及CD4+T细胞和CD8+T细胞计数及各亚群的变化情况。结果 在LPV/r治疗期,LPV/r单独治疗组的血红蛋白在治疗1、2周时明显降低,随后恢复到治疗前水平(P<0.05),益艾康联合LPV/r治疗组则无显著变化(P>0.05);两组动物的肌酐在治疗期间逐渐升高(P<0.05),组间差异无统计学意义(P>0.05);LPV/r单独治疗组的γ-谷氨酰转肽酶在各时间点均高于益艾康联合LPV/r治疗组,但差异无统计学意义(P>0.05);益艾康联合LPV/r治疗组PD-1^(+)CD_(4)^(+)T细胞百分比治疗后升高(P<0.05),LPV/r单独治疗组无明显变化(P>0.05),益艾康联合LPV/r治疗组PD-1^(+)CD_(4)^(+)T细胞百分比在治疗期间均低于LPV/r单独治疗组,但差异无统计学意义(P>0.05);益艾康联合LPV/r治疗组na6ve CD_(4)^(+)T细胞百分比治疗后降低(P<0.05),LPV/r单独治疗组na6ve CD_(4)^(+)T细胞百分比无明显变化(P>0.05);益艾康联合LPV/r治疗组CD4+Tcm细胞百分比治疗后升高(P<0.05),LPV/r单独治疗组CD_(4)^(+)Tcm细胞百分比无明显变化(P>0.05);使用FTC+PMPA+RAL治疗后,治疗组血浆病毒载量在治疗1周时下降1.80 log10copies/mL,益艾康联合FTC+PMPA+RAL治疗组下降2.40 log10copies/mL,均下降到检测线(1.47 log10copies/mL)以下,停药1周时未见血浆病毒载量反弹,停药2周时益艾康联合FTC+PMPA+RAL治疗组血浆病毒载量出现反弹为2.33 log10copies/mL,FTC+PMPA+RAL治疗组未见反弹,停药3周后两组均出现血浆病毒载量反弹。结论 研究结果表明益艾康联合LPV/r治疗SIVmac239感染猕猴Objective To evaluate the efficacy of Yiaikang(益艾康)combined with antiretroviral therapy(ART)in the treatment of simian immunodeficiency virus(SIVmac239)infected rhesus monkey AIDS model.Methods Eight SIVmac239 infected macaques were randomly divided into two groups.In the ART treatment group and Yiaikang combined with ART treatment group,lopinavir/ritonavir(LPV/r)and FTC+PMPA+RAL were successively used for ART treatment,and the body weight,blood routine,blood biochemistry,plasma viral load,CD_(4)^(+)T cell and CD_(4)^(+)T cell count,and the changes of each subgroup were detected at different treatment periods.Results Hemoglobin in the LPV/r group decreased significantly after 1-2 weeks of treatment and then returned to the pre-treatment level(P<0.05),there was no significant change in the treatment group of Yiaikang combined with LPV/r(P>0.05).Creatinine in both groups increased gradually during treatment(P<0.05),there was no significant difference between groups(P>0.05).The-glutamyl transpeptidase in LPV/r alone group was higher than that in Yiaikang combined with LPV/r group at all times points,and there was no significant difference(P>0.05).The percentage of PD-1^(+)CD_(4)^(+)Tcells increased after treatment in the Yiaikang combined with LPV/r group(P<0.05),there was no significant change in LPV/r in the treatment group alone(P>0.05),the percentage of PD-1^(+)CD_(4)^(+)T cells in the Yiaikang combined with LPV/r group was lower than that in the LPV/r alone group,but there was no significant dfference(P>0.05).The percentage of naive CD_(4)^(+)T cells decreased after treatment in the Yiaikang combined with LPV/r group(P<0.05),there was no significant change in naive CD_(4)^(+) T cell percentage in LPV/r alone group(P>0.05).The percentage of CD_(4)^(+)Tcm cells increased after treatment in the Yiaikang combined with LPV/r group(P<0.05),there was no significant change in the percentage of CD_(4)^(+)Tcm cells in LPV/r alone group(P>0.05).Plasma viral load in the FTC+PMPA+RAL group decreased by 1.80 logio copi

关 键 词：益艾康 克力芝 猴免疫缺陷病毒 ART 猕猴 艾滋病模型 

分 类 号：R512.91[医药卫生—内科学]